完全切除的胚胎型横纹肌肉瘤:EpSSG RMS2005研究经验
该前瞻性研究纳入178例初诊完全切除(IRS I组)且淋巴结阴性(N0)的局限性胚胎型横纹肌肉瘤患者,按低危(A组70例)和标危(B组108例)给予减量化疗。A组8疗程长春新碱+放线菌素D(VA)22周,B组4疗程VA+异环磷酰胺(IVA)后5疗程VA共25周。5年EFS 90.8%、OS 95.7%,A组EFS 95.5%、OS 100%,B组EFS 87.8%、OS 93.0%;4例极年幼患者发生Bearman 2级静脉闭塞病(VOD)。
要点
- 低危ERMS(<10岁且肿瘤≤5cm)完全切除后8疗程VA方案5年EFS 95.5%、OS 100%。
- 标危ERMS完全切除后4疗程IVA+5疗程VA方案5年EFS 87.8%、OS 93.0%。
- 极年幼患者需密切监测肝毒性,警惕静脉闭塞病(VOD)。
核心结论
- 低危ERMS完全切除后8疗程VA方案有效且耐受良好。
- 标危ERMS采用4疗程IVA+5疗程VA替代9疗程IVA亦获良好结果。
- 极年幼患者需密切监测肝毒性。
研究设计与样本
- 纳入初诊镜下完全切除(IRS I组)且淋巴结阴性(N0)的局限性ERMS患者178例。
- 低危A组70例(年龄<10岁且肿瘤≤5cm),标危B组108例(年龄≥10岁或肿瘤>5cm)。
主要发现
- 全组5年EFS 90.8%(95%CI 85.0-94.4),5年OS 95.7%(95%CI 90.5-98.1),n=178。
- A组5年EFS 95.5%(95%CI 86.8-98.5),OS 100%。
- B组5年EFS 87.8%(95%CI 79.3-93.0),OS 93.0%(95%CI 84.8-96.8)。
- 4例极年幼患者发生Bearman 2级静脉闭塞病(VOD)。
关键数值与推荐
- A组:8疗程长春新碱+放线菌素D(VA),共22周。
- B组:4疗程VA+异环磷酰胺(IVA)后5疗程VA,共25周。
- 低危定义:年龄<10岁且肿瘤大小≤5cm;标危:年龄≥10岁或肿瘤>5cm。
临床怎么用
- 完全切除的低危ERMS可减量至8疗程VA化疗。
- 标危完全切除ERMS可用4疗程IVA+5疗程VA替代9疗程IVA。
- 极年幼患者化疗期间需密切监测肝毒性及VOD。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rhabdomyosarcoma (RMS) is the most common form of soft tissue sarcoma in children. We report the results of the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study, which prospectively evaluated the reduction of chemotherapy in patients with embryonal RMS (ERMS) after initial surgery. METHODS: Between October 2005 and December 2016, all patients with localised ERMS with an initial microscopically complete resection (IRS group I) with lymph node-negative (N0) were prospectively enrolled in the low-risk (n = 70, subgroup A; age < 10 years and tumour size ≤ 5 cm) or standard-risk group (n = 108, subgroup B; age ≥ 10 years or tumour size > 5 cm. Subgroup A received 8 courses of vincristine and dactinomycin (VA) for 22 weeks; subgroup B received 4 courses of VA with ifosfamide (IVA) and 5 courses of VA for 25 weeks. RESULTS: The 5-year event-free survival (EFS) and overall survival (OS) were 90.8% (95% confidence interval [CI]: 85.0-94.4) and 95.7% (95% CI: 90.5-98.1), respectively (n = 178). The EFS and OS were 95.5% (95% CI: 86.8-98.5) and 100% (subgroupA), and 87.8% (95% CI: 79.3-93.0) and 93.0% (95% CI: 84.8-96.8)(subgroup B), respectively. Bearman stage 2 veno-occlusive disease (VOD) occurred in 4 very young patients. CONCLUSION: VA treatment for 8 courses was effective and well tolerated by the subgroup of patients with low-risk ERMS (group A). Four courses of IVA and 5 courses of VA instead of 9 courses of IVA also has very good results. Careful monitoring for liver toxicity is important in very young patients. European union drug regulating authorities clinical trials EUDRACT No. 2005-000217-35.
引用
- Bergeron C, Jenney M, De Corti F, et al. Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience. Eur J Cancer. 2021. PMID: 33567392. doi:10.1016/j.ejca.2020.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。